Application of Epigenome-Modifying Small Molecules in Induced Pluripotent Stem Cells

Medicinal Research Reviews

Volumn 33, Issue 4, 2013, Pages 790-822

  Lu, Junyan ^a,b   Kong, Xiangqian ^b,c   Luo, Cheng ^a,b   Kathy Li, Keqin ^c  

^a SOOCHOW UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^c SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

DNA methylation; Epigenetics; Histone modification small molecule inhibitor; Induced pluripotent stem cells

Indexed keywords

AZACITIDINE; DNA METHYLTRANSFERASE; HISTONE ACETYLTRANSFERASE; HISTONE METHYLTRANSFERASE;

ARTICLE; CHROMATIN; DNA METHYLATION; EPIGENETICS; EPIGENOME MODIFYING SMALL MOLECULE; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; MYELODYSPLASTIC SYNDROME; NONHUMAN; PLURIPOTENT STEM CELL;

ANIMALS; DRUG EVALUATION, PRECLINICAL; EPIGENOMICS; HISTONES; HUMANS; INDUCED PLURIPOTENT STEM CELLS; SMALL MOLECULE LIBRARIES;

EID: 84878629660     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21265     Document Type: Article

References (182)

1. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126(4):663-676.
2. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131(5):861-872.
3. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin, II, Thomson JA. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007;318(5858):1917-1920.
4. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, Lerou PH, Lensch MW, Daley GQ. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008;451(7175):141-146.
5. Hochedlinger K, Maherali N. Guidelines and Techniques for the Generation of Induced Pluripotent Stem Cells. Cell Stem Cell 2008;3(6):595-605.
6. Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008;322(5903):949-953.
7. Stadtfeld M, Nagaya M, Utikal J, Weir G, Hochedlinger K. Induced pluripotent stem cells generated without viral integration. Science 2008;322(5903):945-949.
8. Woltjen K, Michael IP, Mohseni P, Desai R, Mileikovsky M, Hamalainen R, Cowling R, Wang W, Liu P, Gertsenstein M, Kaji K, Sung HK, Nagy A. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 2009;458(7239):766-770.
9. Kaji K, Norrby K, Paca A, Mileikovsky M, Mohseni P, Woltjen K. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 2009;458(7239):771-775.
10. Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, Slukvin, II, Thomson JA. Human induced pluripotent stem cells free of vector and transgene sequences. Science 2009;324(5928):797-801.
11. Wernig M, Meissner A, Cassady JP, Jaenisch R. c-Myc is dispensable for direct reprogramming of mouse fibroblasts. Cell Stem Cell 2008;2(1):10-12.
12. Kim JB, Zaehres H, Wu G, Gentile L, Ko K, Sebastiano V, Arauzo-Bravo MJ, Ruau D, Han DW, Zenke M, Scholer HR. Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors. Nature 2008;454(7204):646-650.
13. Orlando V. Polycomb, epigenomes, and control of cell identity. Cell 2003;112(5):599-606.
14. Wolffe AP, Matzke MA. Epigenetics: Regulation through repression. Science 1999;286(5439):481-486.
15. Bernstein E, Ang YS, Gaspar-Maia A, Lemischka IR. Stem cells and reprogramming: breaking the epigenetic barrier? Trends Pharmacol Sci 2011;32(7):394-401.
16. Yamanaka S. Elite and stochastic models for induced pluripotent stem cell generation. Nature 2009;460(7251):49-52.
17. Hanna J, Saha K, Pando B, van Zon J, Lengner CJ, Creyghton MP, van Oudenaarden A, Jaenisch R. Direct cell reprogramming is a stochastic process amenable to acceleration. Nature 2009;462(7273):595-601.
18. Wakao S, Kitada M, Kuroda Y, Shigemoto T, Matsuse D, Akashi H, Tanimura Y, Tsuchiyama K, Kikuchi T, Goda M, Nakahata T, Fujiyoshi Y, Dezawa M. Multilineage-differentiating stress-enduring (Muse) cells are a primary source of induced pluripotent stem cells in human fibroblasts. Proc Natl Acad Sci USA 2011; 108(24): 9875-9880.
19. Kuroda Y, Kitada M, Wakao S, Nishikawa K, Tanimura Y, Makinoshima H, Goda M, Akashi H, Inutsuka A, Niwa A, Shigemoto T, Nabeshima Y, Nakahata T, Fujiyoshi Y, Dezawa M. Unique multipotent cells in adult human mesenchymal cell populations. Proc Natl Acad Sci USA 2010;107(19):8639-8643.
20. Waddington CH. The Strategy of the Genes London: Allen &Unwin; 1957.
21. Bird AP. CpG-rich islands and the function of DNA methylation. Nature 1986;321(6067):209-213.
22. Li E, Beard C, Jaenisch R. Role for DNA methylation in genomic imprinting. Nature 1993;366(6453):362-365.
23. Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. J Mol Biol 1987;196(2):261-282.
24. Bird AP, Wolffe AP. Methylation-induced repression-Belts, braces, and chromatin. Cell 1999;99(5):451-454.
25. Siegfried Z, Eden S, Mendelsohn M, Feng X, Tsuberi BZ, Cedar H. DNA methylation represses transcription in vivo. Nat Genet 1999;22(2):203-206.
26. Kass SU, Landsberger N, Wolffe AP. DNA methylation directs a time-dependent repression of transcription initiation. Curr Biol: CB 1997;7(3):157-165.
27. Keshet I, Yisraeli J, Cedar H. Effect of regional DNA methylation on gene expression. Proc Natl Acad Sci USA 1985;82(9):2560-2564.
28. Cedar H. DNA methylation and gene activity. Cell 1988;53(1):3-4.
29. Imamura M, Miura K, Iwabuchi K, Ichisaka T, Nakagawa M, Lee J, Kanatsu-Shinohara M, Shinohara T, Yamanaka S. Transcriptional repression and DNA hypermethylation of a small set of ES cell marker genes in male germline stem cells. BMC Dev Biol 2006;6:34.
30. Kass SU, Pruss D, Wolffe AP. How does DNA methylation repress transcription? Trends Genet 1997;13(11):444-449.
31. Hajkova P, Ancelin K, Waldmann T, Lacoste N, Lange UC, Cesari F, Lee C, Almouzni G, Schneider R, Surani MA. Chromatin dynamics during epigenetic reprogramming in the mouse germ line. Nature 2008;452(7189):877-881.
32. Jaenisch R, Bird A. Epigenetic regulation of gene expression: How the genome integrates intrinsic and environmental signals. Nat Genet 2003;33 Suppl:245-254.
33. Feldman N, Gerson A, Fang J, Li E, Zhang Y, Shinkai Y, Cedar H, Bergman Y. G9a-mediated irreversible epigenetic inactivation of Oct-3/4 during early embryogenesis. Nat Cell Biol 2006;8(2):188-194.
34. Mikkelsen TS, Hanna J, Zhang X, Ku M, Wernig M, Schorderet P, Bernstein BE, Jaenisch R, Lander ES, Meissner A. Dissecting direct reprogramming through integrative genomic analysis. Nature 2008;454(7200):49-55.
35. Sridharan R, Tchieu J, Mason MJ, Yachechko R, Kuoy E, Horvath S, Zhou Q, Plath K. Role of the murine reprogramming factors in the induction of pluripotency. Cell 2009;136(2):364-377.
36. Jones PA, Liang GN. OPINION Rethinking how DNA methylation patterns are maintained. Nat Rev Genet 2009;10(11):805-811.
37. Lin IG, Tomzynski TJ, Ou Q, Hsieh CL. Modulation of DNA binding protein affinity directly affects target site demethylation. Mol Cell Biol 2000;20(7):2343-2349.
38. Chiu CP, Blau HM. 5-Azacytidine permits gene activation in a previously noninducible cell type. Cell 1985;40(2):417-424.
39. Huangfu D, Maehr R, Guo W, Eijkelenboom A, Snitow M, Chen AE, Melton DA. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol 2008;26(7):795-797.
40. Taylor SM, Jones PA. Multiple new phenotypes induced in 10T1/2 and 3T3 cells treated with 5-azacytidine. Cell 1979;17(4):771-779.
41. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980;20(1):85-93.
42. Santini V. Azacitidine: Activity and efficacy as an epigenetic treatment of myelodysplastic syndromes. Expert Rev Hematol 2009;2(2):121-127.
43. Amatori S, Bagaloni I, Donati B, Fanelli M. DNA demethylating antineoplastic strategies: A comparative point of view. Genes Cancer 2010;1(3):197-209.
44. Issa JP, Kantarjian HM. Targeting DNA methylation. Clin Cancer Res 2009;15(12):3938-3946.
45. Jones PA. Effects of 5-azacytidine and its 2′-deoxyderivative on cell differentiation and DNA methylation. Pharmacol Ther 1985;28(1):17-27.
46. Shi Y, Desponts C, Do JT, Hahm HS, Scholer HR, Ding S. Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. Cell Stem Cell 2008;3(5):568-574.
47. Zielenkiewicz P, Siedlecki P, Boy RG, Musch T, Brueckner B, Suhai S, Lyko F. Discovery of two novel, small-molecule inhibitors of DNA methylation. J Med Chem 2006;49(2):678-683.
48. Lyko F, Brueckner B, Boy RG, Siedlecki P, Musch T, Kliem HC, Zielenkiewicz P, Suhai S, Wiessler M. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Can Res 2005;65(14):6305-6311.
49. Schirrmacher R, Schirrmacher E, Beck C, Brueckner B, Schmitges F, Siedlicki P, Bartenstein P, Lyko F. Synthesis and in vitro evaluation of biotinylated RG108: A high affinity compound for studying binding interactions with human DNA methyltransferases. Bioconjug Chem 2006;17(2):261-266.
50. Ruau D, Ensenat-Waser R, Dinger TC, Vallabhapurapu DS, Rolletschek A, Hacker C, Hieronymus T, Wobus AM, Muller AM, Zenke M. Pluripotency associated genes are reactivated by chromatin-modifying agents in neurosphere cells. Stem Cells 2008;26(4):920-926.
51. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002;21(35):5400-5413.
52. Feinberg AP, Gehrke CW, Kuo KC, Ehrlich M. Reduced genomic 5-methylcytosine content in human colonic neoplasia. Cancer Res 1988;48(5):1159-1161.
53. Szyf M, Pakneshan P, Rabbani SA. DNA demethylation and cancer: Therapeutic implications. Cancer Lett 2004;211(2):133-143.
54. Kouzarides T. Chromatin modifications and their function. Cell 2007;128(4):693-705.
55. Shilatifard A, Lee JS, Smith E. The language of histone crosstalk. Cell 2010;142(5):682-685.
56. Jenuwein T, Allis CD. Translating the histone code. Science 2001;293(5532):1074-1080.
57. Weintraub H, Worcel A, Alberts B. A model for chromatin based upon two symmetrically paired half-nucleosomes. Cell 1976;9(3):409-417.
58. Xu M, Long C, Chen X, Huang C, Chen S, Zhu B. Partitioning of histone H3-H4 tetramers during DNA replication-dependent chromatin assembly. Science 2010;328(5974):94-98.
59. Cockell M, Gotta M, Palladino F, Martin SG, Gasser SM. Targeting Sir proteins to sites of action: A general mechanism for regulated repression. Cold Spring Harb Symp Quant Biol 1998;63:401-412.
60. Margueron R, Justin N, Ohno K, Sharpe ML, Son J, Drury WJ, 3rd, Voigt P, Martin SR, Taylor WR, De Marco V, Pirrotta V, Reinberg D, Gamblin SJ. Role of the polycomb protein EED in the propagation of repressive histone marks. Nature 2009;461(7265):762-767.
61. Grewal SI, Moazed D. Heterochromatin and epigenetic control of gene expression. Science 2003;301(5634):798-802.
62. Scharf AN, Barth TK, Imhof A. Establishment of histone modifications after chromatin assembly. Nucleic acids research 2009;37(15):5032-5040.
63. Zhu B, Reinberg D. Epigenetic inheritance: uncontested? Cell Res 2011;21(3):435-441.
64. Pesavento JJ, Yang H, Kelleher NL, Mizzen CA. Certain and progressive methylation of histone H4 at lysine 20 during the cell cycle. Mol Cell Biol 2008;28(1):468-486.
65. Cedar H, Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 2009;10(5):295-304.
66. Fuks F, Hurd PJ, Wolf D, Nan X, Bird AP, Kouzarides T. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J Biol Chem 2003;278(6):4035-4040.
67. Sarraf SA, Stancheva I. Methyl-CpG binding protein MBD1 couples histone H3 methylation at lysine 9 by SETDB1 to DNA replication and chromatin assembly. Mol Cell 2004;15(4):595-605.
68. Esteve PO, Chin HG, Smallwood A, Feehery GR, Gangisetty O, Karpf AR, Carey MF, Pradhan S. Direct interaction between DNMT1 and G9a coordinates DNA and histone methylation during replication. Genes Dev 2006;20(22):3089-3103.
69. Martin C, Zhang Y. Mechanisms of epigenetic inheritance. Curr Opin Cell Biol 2007;19(3):266-272.
70. Hong L, Schroth GP, Matthews HR, Yau P, Bradbury EM. Studies of the DNA binding properties of histone H4 amino terminus. Thermal denaturation studies reveal that acetylation markedly reduces the binding constant of the H4 "tail" to DNA. J Biol Chem 1993;268(1):305-314.
71. Lee DY, Hayes JJ, Pruss D, Wolffe AP. A positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell 1993;72(1):73-84.
72. Cervoni N, Szyf M. Demethylase activity is directed by histone acetylation. J Biol Chem 2001;276(44):40778-40787.
73. Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev 1999;9(1):40-48.
74. Jeppesen P. Histone acetylation: A possible mechanism for the inheritance of cell memory at mitosis. Bioessays 1997;19(1):67-74.
75. Spinaci M, Seren E, Mattioli M. Maternal chromatin remodeling during maturation and after fertilization in mouse oocytes. Mol Reprod Dev 2004;69(2):215-221.
76. Wang F, Kou Z, Zhang Y, Gao S. Dynamic reprogramming of histone acetylation and methylation in the first cell cycle of cloned mouse embryos. Biol Reprod 2007;77(6):1007-1016.
77. Kim JM, Liu H, Tazaki M, Nagata M, Aoki F. Changes in histone acetylation during mouse oocyte meiosis. J Cell Biol 2003;162(1):37-46.
78. Sarmento OF, Digilio LC, Wang Y, Perlin J, Herr JC, Allis CD, Coonrod SA. Dynamic alterations of specific histone modifications during early murine development. J Cell Sci 2004;117(Pt 19):4449-4459.
79. Akiyama T, Kim JM, Nagata M, Aoki F. Regulation of histone acetylation during meiotic maturation in mouse oocytes. Mol Reprod Dev 2004;69(2):222-227.
80. Rybouchkin A, Kato Y, Tsunoda Y. Role of histone acetylation in reprogramming of somatic nuclei following nuclear transfer. Biol Reprod 2006;74(6):1083-1089.
81. Shiota K, Hattori N, Nishino K, Ko YG, Hattori N, Ohgane J, Tanaka S. Epigenetic control of mouse Oct-4 gene expression in embryonic stem cells and trophoblast stem cells. J Biol Chem 2004;279(17):17063-17069.
82. Tada T, Kimura H, Tada M, Nakatsuji N. Histone code modifications on pluripotential nuclei of reprogrammed somatic cells. Mol Cell Biol 2004;24(13):5710-5720.
83. Eisenman RN, Knoepfler PS, Zhang XY, Cheng PF, Gafken PR, McMahon SB. Myc influences global chromatin structure. EMBO J 2006;25(12):2723-2734.
84. Kuo MH, Allis CD. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 1998;20(8):615-626.
85. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997;389(6649):349-352.
86. Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Gene Dev 1998;12(5):599-606.
87. Van Kuilenburg ABP, De Ruijter AJM, Van Gennip AH, Caron HN, Kemp S. Histone deacetylases (HDACs): Characterization of the classical HDAC family. Biochem J 2003;370:737-749.
88. Johnstone RW. Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002;1(4):287-299.
89. Galasinski SC, Resing KA, Goodrich JA, Ahn NG. Phosphatase inhibition leads to histone deacetylases 1 and 2 phosphorylation and disruption of corepressor interactions. J Biol Chem 2002;277(22):19618-19626.
90. Buggy JJ, Sideris ML, Mak P, Lorimer DD, McIntosh B, Clark JM. Cloning and characterization of a novel human histone deacetylase, HDAC8. Biochem J 2000;350:199-205.
91. Iager AE, Ragina NP, Ross PJ, Beyhan Z, Cunniff K, Rodriguez RM, Cibelli JB. Trichostatin A improves histone acetylation in bovine somatic cell nuclear transfer early embryos. Cloning Stem Cells 2008;10(3):371-379.
92. Bui HT, Wakayama S, Kishigami S, Park KK, Kim JH, Thuan NV, Wakayama T. Effect of trichostatin A on chromatin remodeling, histone modifications, DNA replication, and transcriptional activity in cloned mouse embryos. Biol Reprod 2010;83(3):454-463.
93. Kim YJ, Ahn KS, Kim M, Shim H. Comparison of potency between histone deacetylase inhibitors trichostatin A and valproic acid on enhancing in vitro development of porcine somatic cell nuclear transfer embryos. In Vitro Cell Dev Biol Anim 2011; 47(4): 283-289.
94. Liang G, Taranova O, Xia K, Zhang Y. Butyrate promotes induced pluripotent stem cell generation. J Biol Chem 2010;285(33):25516-25521.
95. Mali P, Chou BK, Yen J, Ye Z, Zou J, Dowey S, Brodsky RA, Ohm JE, Yu W, Baylin SB, Yusa K, Bradley A, Meyers DJ, Mukherjee C, Cole PA, Cheng L. Butyrate greatly enhances derivation of human induced pluripotent stem cells by promoting epigenetic remodeling and the expression of pluripotency-associated genes. Stem Cells 2010;28(4):713-720.
96. Huangfu D, Osafune K, Maehr R, Guo W, Eijkelenboom A, Chen S, Muhlestein W, Melton DA. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol 2008;26(11):1269-1275.
97. Zhou H, Wu S, Joo JY, Zhu S, Han DW, Lin T, Trauger S, Bien G, Yao S, Zhu Y, Siuzdak G, Scholer HR, Duan L, Ding S. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 2009;4(5):381-384.
98. Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 2004;64(3):1079-1086.
99. Marmorstein R, Trievel RC. Histone modifying enzymes: Structures, mechanisms, and specificities. Biochim Biophys Acta 2009;1789(1):58-68.
100. Tian X, Fang J. Current perspectives on histone demethylases. Acta Biochim Biophys Sin (Shanghai) 2007;39(2):81-88.
101. Li KK, Luo C, Wang D, Jiang H, Zheng YG. Chemical and biochemical approaches in the study of histone methylation and demethylation. Med Res Rev 2010. DOI: 10.1002/med.20228
102. Hebbes TR, Thorne AW, Crane-Robinson C. A direct link between core histone acetylation and transcriptionally active chromatin. EMBO J 1988;7(5):1395-1402.
103. Litt MD, Simpson M, Gaszner M, Allis CD, Felsenfeld G. Correlation between histone lysine methylation and developmental changes at the chicken beta-globin locus. Science 2001;293(5539):2453-2455.
104. Nakayama J, Rice JC, Strahl BD, Allis CD, Grewal SI. Role of histone H3 lysine 9 methylation in epigenetic control of heterochromatin assembly. Science 2001;292(5514):110-113.
105. Plath K, Fang J, Mlynarczyk-Evans SK, Cao R, Worringer KA, Wang H, de la Cruz CC, Otte AP, Panning B, Zhang Y. Role of histone H3 lysine 27 methylation in X inactivation. Science 2003;300(5616):131-135.
106. Kang L, Wang J, Zhang Y, Kou Z, Gao S. iPS cells can support full-term development of tetraploid blastocyst-complemented embryos. Cell Stem Cell 2009;5(2):135-138.
107. Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K, Bernstein BE, Jaenisch R. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 2007;448(7151):318-324.
108. Boland MJ, Hazen JL, Nazor KL, Rodriguez AR, Gifford W, Martin G, Kupriyanov S, Baldwin KK. Adult mice generated from induced pluripotent stem cells. Nature 2009;461(7260):91-94.
109. Shafa M, Krawetz R, Rancourt DE. Returning to the stem state: epigenetics of recapitulating pre-differentiation chromatin structure. Bioessays 2010;32(9):791-799.
110. Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J, Fry B, Meissner A, Wernig M, Plath K, Jaenisch R, Wagschal A, Feil R, Schreiber SL, Lander ES. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006;125(2):315-326.
111. Azuara V, Perry P, Sauer S, Spivakov M, Jorgensen HF, John RM, Gouti M, Casanova M, Warnes G, Merkenschlager M, Fisher AG. Chromatin signatures of pluripotent cell lines. Nature Cell Biology 2006;8(5):532-U189.
112. Ringrose L, Paro R. Epigenetic regulation of cellular memory by the Polycomb and Trithorax group proteins. Ann Rev Genet 2004;38:413-443.
113. Surface LE, Thornton SR, Boyer LA. Polycomb group proteins set the stage for early lineage commitment. Cell Stem Cell 2010;7(3):288-298.
114. Schuettengruber B, Chourrout D, Vervoort M, Leblanc B, Cavalli G. Genome regulation by polycomb and trithorax proteins. Cell 2007;128(4):735-745.
115. Prezioso C, Orlando V. Polycomb proteins in mammalian cell differentiation and plasticity. FEBS Lett 2011;585(13):2067-2077.
116. Landeira D, Fisher AG. Inactive yet indispensable: The tale of Jarid2. Trends Cell Biol 2011;21(2):74-80.
117. Ng HH, Loh YH, Zhang WW, Chen X, George J. Jmjd1a and Jmjd2c histone H3 Lys 9 demethylases regulate self-renewal in embryonic stem cells. Gene Dev 2007;21(20):2545-2557.
118. Shi Y, Do JT, Desponts C, Hahm HS, Scholer HR, Ding S. A combined chemical and genetic approach for the generation of induced pluripotent stem cells. Cell Stem Cell 2008;2(6):525-528.
119. Tachibana M, Sugimoto K, Fukushima T, Shinkai Y. Set domain-containing protein, G9a, is a novel lysine-preferring mammalian histone methyltransferase with hyperactivity and specific selectivity to lysines 9 and 27 of histone H3. J Biol Chem 2001;276(27):25309-25317.
120. Tachibana M, Sugimoto K, Nozaki M, Ueda J, Ohta T, Ohki M, Fukuda M, Takeda N, Niida H, Kato H, Shinkai Y. G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. Genes Dev 2002;16(14):1779-1791.
121. Yokochi T, Poduch K, Ryba T, Lu J, Hiratani I, Tachibana M, Shinkai Y, Gilbert DM. G9a selectively represses a class of late-replicating genes at the nuclear periphery. Proc Natl Acad Sci USA 2009;106(46):19363-19368.
122. Lee KS, Yoon J, Park JS, Kang YK. Drosophila G9a is implicated in germ cell development. Insect Mol Biol 2010;19(1):131-139.
123. Lehnertz B, Northrop JP, Antignano F, Burrows K, Hadidi S, Mullaly SC, Rossi FM, Zaph C. Activating and inhibitory functions for the histone lysine methyltransferase G9a in T helper cell differentiation and function. J Exp Med 2010;207(5):915-922.
124. Epsztejn-Litman S, Feldman N, Abu-Remaileh M, Shufaro Y, Gerson A, Ueda J, Deplus R, Fuks F, Shinkai Y, Cedar H, Bergman Y. De novo DNA methylation promoted by G9a prevents reprogramming of embryonically silenced genes. Nat Struct Mol Biol 2008;15(11):1176-1183.
125. Yuan X, Wan H, Zhao X, Zhu S, Zhou Q, Ding S. Combined chemical treatment enables Oct4-induced reprogramming from mouse embryonic fibroblasts. Stem Cells 2011; 29(3):549-553.
126. Li Y, Zhang Q, Yin X, Yang W, Du Y, Hou P, Ge J, Liu C, Zhang W, Zhang X, Wu Y, Li H, Liu K, Wu C, Song Z, Zhao Y, Shi Y, Deng H. Generation of iPSCs from mouse fibroblasts with a single gene, Oct4, and small molecules. Cell Res 2011;21(1):196-204.
127. Wang Q, Xu X, Li J, Liu J, Gu H, Zhang R, Chen J, Kuang Y, Fei J, Jiang C, Wang P, Pei D, Ding S, Xie X. Lithium, an anti-psychotic drug, greatly enhances the generation of induced pluripotent stem cells. Cell Res 2011; 21(10) 1424-1435.
128. He YF, Li BZ, Li Z, Liu P, Wang Y, Tang Q, Ding J, Jia Y, Chen Z, Li L, Sun Y, Li X, Dai Q, Song CX, Zhang K, He C, Xu GL. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 2011;333(6047):1303-1307.
129. Rawat VPS, Mohr F, Dohner K, Buske C. TET genes: New players in DNA demethylation and important determinants for stemness. Exp Hematol 2011;39(3):272-281.
130. Koh KP, Yabuuchi A, Rao S, Huang Y, Cunniff K, Nardone J, Laiho A, Tahiliani M, Sommer CA, Mostoslavsky G, Lahesmaa R, Orkin SH, Rodig SJ, Daley GQ, Rao A. Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. Cell Stem Cell 2011;8(2):200-213.
131. Bhutani N, Brady JJ, Damian M, Sacco A, Corbel SY, Blau HM. Reprogramming towards pluripotency requires AID-dependent DNA demethylation. Nature 2010;463(7284):1042-1047.
132. Liu DR, Tahiliani M, Koh KP, Shen YH, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Aravind L, Rao A. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009;324(5929):930-935.
133. Kriaucionis S, Heintz N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 2009;324(5929):929-930.
134. Ficz G, Branco MR, Seisenberger S, Santos F, Krueger F, Hore TA, Marques CJ, Andrews S, Reik W. Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation. Nature 2011;473(7347):398-402.
135. Xu Y, Wu F, Tan L, Kong L, Xiong L, Deng J, Barbera AJ, Zheng L, Zhang H, Huang S, Min J, Nicholson T, Chen T, Xu G, Shi Y, Zhang K, Shi YG. Genome-wide regulation of 5hmC, 5mC, and gene expression by Tet1 hydroxylase in mouse embryonic stem cells. Mol Cell 2011;42(4):451-464.
136. Walsh CP, Xu GL. Cytosine methylation and DNA repair. Curr Top Microbiol Immunol 2006;301:283-315.
137. McGhee KA, Morris DW, Schwaiger S, Nangle JM, Donohoe G, Clarke S, Meagher D, Quinn J, Scully P, Waddington JL, Gill M, Corvin A. Investigation of the apolipoprotein-L (APOL) gene family and schizophrenia using a novel DNA pooling strategy for public database SNPs. Schizophr Res 2005;76(2-3):231-238.
138. Crabtree GR, Ho L. Chromatin remodelling during development. Nature 2010;463(7280):474-484.
139. Ramalho-Santos M, Gaspar-Maia A, Alajem A, Polesso F, Sridharan R, Mason MJ, Heidersbach A, Ramalho-Santos J, McManus MT, Plath K, Meshorer E. Chd1 regulates open chromatin and pluripotency of embryonic stem cells. Nature 2009;460(7257):863-U897.
140. Paddison PJ, Schaniel C, Ang YS, Ratnakumar K, Cormier C, James T, Bernstein E, Lemischka IR. Smarcc1/Baf155 couples self-renewal gene repression with changes in chromatin structure in mouse embryonic stem cells. Stem Cells 2009;27(12):2979-2991.
141. Hendrich B, Kaji K, Caballero IM, MacLeod R, Nichols J, Wilson VA. The NuRD component Mbd3 is required for pluripotency of embryonic stem cells. Nat Cell Biol 2006;8(3):285-292.
142. Festenstein R, Pagakis SN, Hiragami K, Lyon D, Verreault A, Sekkali B, Kioussis D. Modulation of heterochromatin protein 1 dynamics in primary mammalian cells. Science 2003;299(5607):719-721.
143. Henikoff S, Ahmad K. The histone variant H3.3 marks active chromatin by replication-independent nucleosome assembly. Mol Cell 2002;9(6):1191-1200.
144. Redon C, Boon C, Johnson K, Bonner WM, Rogakou EP. Megabase chromatin domains involved in DNA double-strand breaks in vivo. Mol Biol Cell 1999;10:282a-282a.
145. Hendzel MJ, Lever MA, Th'ng JPH, Sun XJ. Rapid exchange of histone H1.1 on chromatin in living human cells. Nature 2000;408(6814):873-876.
146. Misteli T, Gunjan A, Hock R, Bustin M, Brown DT. Dynamic binding of histone H1 to chromatin in living cells. Nature 2000;408(6814):877-881.
147. Misteli T, Phair RD, Scaffidi P, Elbi C, Vecerova J, Dey A, Ozato K, Brown DT, Hager G, Bustin M. Global nature of dynamic protein-chromatin interactions in vivo: Three-dimensional genome scanning and dynamic interaction networks of chromatin proteins. Mol Cell Biol 2004;24(14):6393-6402.
148. Misteli T, Meshorer E, Yellajoshula D, George E, Scambler PJ, Brown DT. Hyperdynamic plasticity in pluripotent embryonic of chromatin proteins stem cells. Dev Cell 2006;10(1):105-116.
149. Gonzalez F, Barragan Monasterio M, Tiscornia G, Montserrat Pulido N, Vassena R, Batlle Morera L, Rodriguez Piza I, Izpisua Belmonte JC. Generation of mouse-induced pluripotent stem cells by transient expression of a single nonviral polycistronic vector. Proc Natl Acad Sci USA 2009;106(22):8918-8922.
150. Kim D, Kim CH, Moon JI, Chung YG, Chang MY, Han BS, Ko S, Yang E, Cha KY, Lanza R, Kim KS. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 2009;4(6):472-476.
151. Hussein SM, Batada NN, Vuoristo S, Ching RW, Autio R, Narva E, Ng S, Sourour M, Hamalainen R, Olsson C, Lundin K, Mikkola M, Trokovic R, Peitz M, Brustle O, Bazett-Jones DP, Alitalo K, Lahesmaa R, Nagy A, Otonkoski T. Copy number variation and selection during reprogramming to pluripotency. Nature 2011;471(7336):58-62.
152. Lister R, Pelizzola M, Kida YS, Hawkins RD, Nery JR, Hon G, Antosiewicz-Bourget J, O'Malley R, Castanon R, Klugman S, Downes M, Yu R, Stewart R, Ren B, Thomson JA, Evans RM, Ecker JR. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 2011;471(7336):68-73.
153. Gore A, Li Z, Fung HL, Young JE, Agarwal S, Antosiewicz-Bourget J, Canto I, Giorgetti A, Israel MA, Kiskinis E, Lee JH, Loh YH, Manos PD, Montserrat N, Panopoulos AD, Ruiz S, Wilbert ML, Yu J, Kirkness EF, Izpisua Belmonte JC, Rossi DJ, Thomson JA, Eggan K, Daley GQ, Goldstein LS, Zhang K. Somatic coding mutations in human induced pluripotent stem cells. Nature 2011;471(7336):63-67.
154. Pera MF. Stem cells: The dark side of induced pluripotency. Nature 2011;471(7336):46-47.
155. Brummelkamp TR, Carette JE, Pruszak J, Varadarajan M, Blomen VA, Gokhale S, Camargo FD, Wernig M, Jaenisch R. Generation of iPSCs from cultured human malignant cells. Blood 2010;115(20):4039-4042.
156. Chang G, Miao YL, Zhang Y, Liu S, Kou ZH, Ding JJ, Chen DY, Sun QY, Gao SR. Linking Incomplete Reprogramming to the Improved Pluripotency of Murine Embryonal Carcinoma Cell-Derived Pluripotent Stem Cells. PloS one 2010;5(4) e10320.
157. Hochedlinger K, Utikal J, Polo JM, Stadtfeld M, Maherali N, Kulalert W, Walsh RM, Khalil A, Rheinwald JG. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature 2009;460(7259):1145-U1112.
158. Ishii H, Miyoshi N, Nagai K, Hoshino H, Mimori K, Tanaka F, Nagano H, Sekimoto M, Doki Y, Mori M. Defined factors induce reprogramming of gastrointestinal cancer cells. P Natl Acad Sci USA 2010;107(1):40-45.
159. Lin SL, Chang DC, Chang-Lin S, Lin CH, Wu DTS, Chen DT, Ying SY. Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state. RNA 2008;14(10):2115-2124.
160. Sun C, Liu YK. Induced pluripotent cancer cells: progress and application. J Cancer Res Clin Oncol 2011;137(1):1-8.
161. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414(6859):105-111.
162. Lyssiotis CA, Foreman RK, Staerk J, Garcia M, Mathur D, Markoulaki S, Hanna J, Lairson LL, Charette BD, Bouchez LC, Bollong M, Kunick C, Brinker A, Cho CY, Schultz PG, Jaenisch R. Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4. Proc Natl Acad Sci USA 2009;106(22):8912-8917.
163. Fusaki N, Ban H, Nishiyama A, Saeki K, Hasegawa M. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc Jpn Acad Ser B, Phys Biol Sci 2009;85(8):348-362.
164. Ban H, Nishishita N, Fusaki N, Tabata T, Saeki K, Shikamura M, Takada N, Inoue M, Hasegawa M, Kawamata S, Nishikawa S. Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors. Proc Natl Acad Sci USA 2011;108(34):14234-14239.
165. Helgason CD, Palmqvist L, Glover CH, Hsu L, Lu M, Bossen B, Piret JM, Humphries RK. Correlation of murine embryonic stem cell gene expression profiles with functional measures of pluripotency. Stem Cells 2005;23(5):663-680.
166. Andrews PW, Draper JS, Pigott C, Thomson JA. Surface antigens of human embryonic stem cells: Changes upon differentiation in culture. J Anat 2002;200(3):249-258.
167. Andrews PW, Draper JS, Moore HD, Ruban LN, Gokhale PJ. Culture and characterization of human embryonic stem cells. Stem Cells Dev 2004;13(4):325-336.
168. Carpenter MK, Hoffman LM. Characterization and culture of human embryonic stem cells. Nat Biotechnol 2005;23(6):699-708.
169. Kuo HC, Chen HF, Chuang CY, Lee WC, Huang HP, Wu HC, Ho HN, Chen YJ. Surface marker epithelial cell adhesion molecule and E-cadherin facilitate the identification and selection of induced pluripotent stem cells. Stem Cell Rev Rep 2011;7(3):722-735.
170. Masaki H, Ishikawa T, Takahashi S, Okumura M, Sakai N, Haga M, Kominami K, Migita H, McDonald F, Shimada F, Sakurada K. Heterogeneity of pluripotent marker gene expression in colonies generated in human iPS cell induction culture. Stem cell Res 2007;1(2):105-115.
171. Adewumi O, Aflatoonian B, Ahrlund-Richter L, Amit M, Andrews PW, Beighton G, Bello PA, Benvenisty N, Berry LS, Bevan S, Blum B, Brooking J, Chen KG, Choo AB, Churchill GA, Corbel M, Damjanov I, Draper JS, Dvorak P, Emanuelsson K, Fleck RA, Ford A, Gertow K, Gertsenstein M, Gokhale PJ, Hamilton RS, Hampl A, Healy LE, Hovatta O, Hyllner J, Imreh MP, Itskovitz-Eldor J, Jackson J, Johnson JL, Jones M, Kee K, King BL, Knowles BB, Lako M, Lebrin F, Mallon BS, Manning D, Mayshar Y, McKay RD, Michalska AE, Mikkola M, Mileikovsky M, Minger SL, Moore HD, Mummery CL, Nagy A, Nakatsuji N, O'Brien CM, Oh SK, Olsson C, Otonkoski T, Park KY, Passier R, Patel H, Patel M, Pedersen R, Pera MF, Piekarczyk MS, Pera RA, Reubinoff BE, Robins AJ, Rossant J, Rugg-Gunn P, Schulz TC, Semb H, Sherrer ES, Siemen H, Stacey GN, Stojkovic M, Suemori H, Szatkiewicz J, Turetsky T, Tuuri T, van den Brink S, Vintersten K, Vuoristo S, Ward D, Weaver TA, Young LA, Zhang W. Characterization of human embryonic stem cell lines by the International Stem Cell Initiative. Nat Biotechnol 2007;25(7):803-816.
172. Chiou SH, Yu CC, Huang CY, Lin SC, Liu CJ, Tsai TH, Chou SH, Chien CS, Ku HH, Lo JF. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer ResRes 2008;14(13):4085-4095.
173. Hart AH, Hartley L, Parker K, Ibrahim M, Looijenga LH, Pauchnik M, Chow CW, Robb L. The pluripotency homeobox gene NANOG is expressed in human germ cell tumors. Cancer 2005;104(10):2092-2098.
174. Ezeh UI, Turek PJ, Reijo RA, Clark AT. Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Cancer 2005;104(10):2255-2265.
175. Heinke R, Spannhoff A, Meier R, Trojer P, Bauer I, Jung M, Sippl W. Virtual screening and biological characterization of novel histone arginine methyltransferase PRMT1 inhibitors. ChemMedChem 2009;4(1):69-77.
176. Spannhoff A, Machmur R, Heinke R, Trojer P, Bauer I, Brosch G, Schule R, Hanefeld W, Sippl W, Jung M. A novel arginine methyltransferase inhibitor with cellular activity. Bioorg Med Chem Lett 2007;17(15):4150-4153.
177. Spannhoff A, Heinke R, Bauer I, Trojer P, Metzger E, Gust R, Schule R, Brosch G, Sippl W, Jung M. Target-based approach to inhibitors of histone arginine methyltransferases. J Med Chem 2007;50(10):2319-2325.
178. Kuck D, Caulfield T, Lyko F, Medina-Franco JL. Nanaomycin A selectively inhibits DNMT3B and reactivates silenced tumor suppressor genes in human cancer cells. Mol Cancer Ther 2010;9(11):3015-3023.
179. Tang H, Wang XS, Huang XP, Roth BL, Butler KV, Kozikowski AP, Jung M, Tropsha A. Novel inhibitors of human histone deacetylase (HDAC) identified by QSAR modeling of known inhibitors, virtual screening, and experimental validation. J Chem Inf Model 2009;49(2):461-476.
180. Ying QL, Wray J, Nichols J, Batlle-Morera L, Doble B, Woodgett J, Cohen P, Smith A. The ground state of embryonic stem cell self-renewal. Nature 2008;453(7194):519-523.
181. Csermely P, Agoston V, Pongor S. The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 2005;26(4):178-182.
182. Hopkins AL. Network pharmacology: The next paradigm in drug discovery. Nat Chem Biol 2008;4(11):682-690.